Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Michael J. Overman(The University of Texas MD Anderson Cancer Center), Thierry André(Inserm), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Rebecca A. Moss(Bristol-Myers Squibb (United States)), Magali Svrcek(Centre Léon Bérard), Jean-Marie Ledeine(Bristol-Myers Squibb (Belgium)), Ka Yeung Mark Wong(Azienda Unita' Sanitaria Locale Di Modena), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Sara Lonardi(Istituto Oncologico Veneto), Massimo Aglietta(Verizon (United States)), Alain Hendlisz(London Cancer), Andrew Hill(University of Auckland), Fabio Gelsomino(University of Modena and Reggio Emilia), Michael B. Sawyer(University of Alberta), Bart Neyns(Universitair Ziekenhuis Brussel), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Z. Alexander Cao(Bristol-Myers Squibb (United States)), Michael A. Morse(Azienda Unita' Sanitaria Locale Di Modena), Shital Kamble(Azienda Unita' Sanitaria Locale Di Modena), Ray McDermott(St. Vincent's University Hospital)
Cited by 2,064
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k